PMID- 37316420
OWN - NLM
STAT- MEDLINE
DCOM- 20230728
LR  - 20230804
IS  - 2212-4411 (Electronic)
VI  - 136
IP  - 2
DP  - 2023 Aug
TI  - Clinical characterization of stomatitis cases with an epithelial growth factor 
      receptor inhibitor in metastatic colorectal cancer patients: A study of 7 cases 
      and literature review.
PG  - 162-172
LID - S2212-4403(23)00005-6 [pii]
LID - 10.1016/j.oooo.2023.01.004 [doi]
AB  - OBJECTIVE: The aim of this study was to report a case series of patients with 
      metastatic colorectal cancer (mCRC) undergoing panitumumab-containing regimens 
      affected by oral lesions and to review the current literature. STUDY DESIGN: 
      Electronic medical records of mCRC patients referred to treat mouth sores during 
      the treatment with the anti-epithelial growth factor receptor 
      (EGFR)-panitumumab-were retrospectively reviewed. Patients' characterization, 
      clinical profile of oral lesions, and management outcomes were documented. 
      Additionally, modifications or discontinuation of the antineoplastic treatment as 
      well as the occurrence of other adverse events (AEs) were analyzed. RESULTS: A 
      total of 7 patients were included. The oral lesions appeared in a median time of 
      10 days (range 7-11 days) after the drug administration. The median reported pain 
      score was 5 (range 1-9), causing feeding discomfort. Oral lesions with a marked 
      aphthous-like appearance, among others, occurred in all cases and involved 
      nonkeratinized mucosa more likely. At least 1 patient had dose reduction of the 
      treatment and 1 patient needed discontinuation due to panitumumab-associated 
      stomatitis. Dermatologic AEs were the most prevalent. Clinical improvement was 
      obtained with topical corticosteroid therapy and/or photobiomodulation. 
      CONCLUSIONS: In summary, panitumumab-containing regimens were associated with a 
      particular pattern of oral lesions consistent with stomatitis. This event may 
      eventually affect the tolerability of the treatment in patients with mCRC.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Gomes-Silva, Wagner
AU  - Gomes-Silva W
AD  - Dental Oncology Service, Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, 
      Brazil. Electronic address: wagner.wgswgs@gmail.com.
FAU - Vechiato-Filho, Aljomar Jose
AU  - Vechiato-Filho AJ
AD  - Dental Oncology Service, Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, 
      Brazil.
FAU - Luiz, Ana Claudia
AU  - Luiz AC
AD  - Dental Oncology Service, Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, 
      Brazil.
FAU - Guollo, Andre
AU  - Guollo A
AD  - School of Dentistry, Universidade Comunitaria da Regiao de Chapeco - Unochapeco, 
      Chapeco, Brazil.
FAU - de Oliveira, Maria Cecilia Querido
AU  - de Oliveira MCQ
AD  - Dental Oncology Service, Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, 
      Brazil.
FAU - Gomes, Mauricio Neves
AU  - Gomes MN
AD  - Dental Oncology Service, Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, 
      Brazil.
FAU - Caparelli, Fernanda Cunha
AU  - Caparelli FC
AD  - Department of Radiology and Oncology, Instituto do Cancer do Estado de Sao Paulo, 
      Sao Paulo, Brazil.
FAU - Brandao, Thais Bianca
AU  - Brandao TB
AD  - Dental Oncology Service, Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, 
      Brazil.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230118
PL  - United States
TA  - Oral Surg Oral Med Oral Pathol Oral Radiol
JT  - Oral surgery, oral medicine, oral pathology and oral radiology
JID - 101576782
RN  - 6A901E312A (Panitumumab)
RN  - 0 (Antibodies, Monoclonal)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - 0 (Receptors, Growth Factor)
SB  - IM
MH  - Humans
MH  - Panitumumab/therapeutic use
MH  - Antibodies, Monoclonal
MH  - *Colorectal Neoplasms/drug therapy/metabolism/pathology
MH  - Retrospective Studies
MH  - ErbB Receptors/metabolism
MH  - Receptors, Growth Factor/therapeutic use
MH  - *Stomatitis/chemically induced/drug therapy
MH  - Antineoplastic Combined Chemotherapy Protocols
COIS- Declarations of interest None.
EDAT- 2023/06/15 01:08
MHDA- 2023/07/28 06:43
CRDT- 2023/06/14 21:56
PHST- 2022/10/31 00:00 [received]
PHST- 2023/01/08 00:00 [revised]
PHST- 2023/01/11 00:00 [accepted]
PHST- 2023/07/28 06:43 [medline]
PHST- 2023/06/15 01:08 [pubmed]
PHST- 2023/06/14 21:56 [entrez]
AID - S2212-4403(23)00005-6 [pii]
AID - 10.1016/j.oooo.2023.01.004 [doi]
PST - ppublish
SO  - Oral Surg Oral Med Oral Pathol Oral Radiol. 2023 Aug;136(2):162-172. doi: 
      10.1016/j.oooo.2023.01.004. Epub 2023 Jan 18.